Muscle Quality is More Impaired in Sarcopenic Patients With Chronic Obstructive Pulmonary Disease

Journal of the American Medical Directors Association

Volumn 17, Issue 5, 2016, Pages 415-420

  van de Bool, Coby ^a   Gosker, Harry R ^a   van den Borst, Bram ^a   Op den Kamp, Celine M ^a   Slot, Ilse G M ^a   Schols, Annemie M W J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

COPD; Muscle fiber; Sarcopenia

Indexed keywords

ADULT; AGED; ARTICLE; BODY COMPOSITION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDURANCE; EXERCISE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE MASS; MUSCLE STRENGTH; PHENOTYPE; QUADRICEPS FEMORIS MUSCLE; SARCOPENIA; COMPLICATION; CROSS-SECTIONAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

AGED; CROSS-SECTIONAL STUDIES; EXERCISE; HUMANS; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCULAR ATROPHY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SARCOPENIA;

EID: 84956686384     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2015.12.094     Document Type: Article

References (44)

1. Engelen M.P., Schols A.M., Baken W.C., et al. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur Respir J 1994, 7:1793-1797.
2. Mostert R., Goris A., Weling-Scheepers C., et al. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med 2000, 94:859-867.
3. Schols A.M., Broekhuizen R., Weling-Scheepers C.A., Wouters E.F. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005, 82:53-59.
4. Marquis K., Debigare R., Lacasse Y., et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:809-813.
5. Schols A.M., Ferreira I.M., Franssen F.M., et al. Nutritional assessment and therapy in COPD: A European Respiratory Society statement. Eur Respir J 2014, 44:1504-1520.
6. Newman A.B., Kupelian V., Visser M., et al. Sarcopenia: Alternative definitions and associations with lower extremity function. J Am Geriatr Soc 2003, 51:1602-1609.
7. Mui T.S., Man J.M., McElhaney J.E., et al. Telomere length and chronic obstructive pulmonary disease: Evidence of accelerated aging. J Am Geriatr Soc 2009, 57:2372-2374.
8. van de Bool C., Rutten E.P., Franssen F.M., et al. Antagonistic implications of sarcopenia and abdominal obesity on physical performance in COPD. Eur Respir J 2015, 46:336-345.
9. Bernard S., LeBlanc P., Whittom F., et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158:629-634.
10. Allaire J., Maltais F., Doyon J.F., et al. Peripheral muscle endurance and the oxidative profile of the quadriceps in patients with COPD. Thorax 2004, 59:673-678.
11. Mathur S., Brooks D., Carvalho C.R. Structural alterations of skeletal muscle in copd. Front Physiol 2014, 5:104.
12. Gosker H.R., Engelen M.P., van Mameren H., et al. Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr 2002, 76:113-119.
13. Gosker H.R., Zeegers M.P., Wouters E.F., Schols A.M., et al. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: A systematic review and meta-analysis. Thorax 2007, 62:944-949.
14. van den Borst B., Slot I.G., Hellwig V.A., et al. Loss of quadriceps muscle oxidative phenotype and decreased endurance in patients with mild-to-moderate COPD. J Appl Physiol (1985) 2013, 114:1319-1328.
15. Wang Y., Pessin J.E. Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care 2013, 16:243-250.
16. Schakman O., Kalista S., Barbe C., et al. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013, 45:2163-2172.
17. de Theije C.C., Langen R.C., Lamers W.H., et al. Differential sensitivity of oxidative and glycolytic muscles to hypoxia-induced muscle atrophy. J Appl Physiol (1985) 2015, 118:200-211.
18. Gosker H.R., van Mameren H., van Dijk P.J., et al. Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J 2002, 19:617-625.
19. Rabinovich R.A., Bastos R., Ardite E., et al. Mitochondrial dysfunction in COPD patients with low body mass index. Eur Respir J 2007, 29:643-650.
20. Remels A.H., Gosker H.R., Schrauwen P., et al. TNF-alpha impairs regulation of muscle oxidative phenotype: Implications for cachexia?. FASEB J 2010, 24:5052-5062.
21. Gouzi F., Abdellaoui A., Molinari N., et al. Fiber atrophy, oxidative stress, and oxidative fiber reduction are the attributes of different phenotypes in chronic obstructive pulmonary disease patients. J Appl Physiol (1985) 2013, 115:1796-1805.
22. Op den Kamp C.M., Langen R.C., Snepvangers F.J., et al. Nuclear transcription factor kappa B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr 2013, 98:738-748.
23. Vestbo J., Hurd S.S., Agusti A.G., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
24. Clausen J.L., Coates A.L., Quanjer P.H. Measurement of lung volumes in humans: Review and recommendations from an ATS/ERS workshop. Eur Respir J 1997, 10:1205-1206.
25. Chung J.H., Hwang H.J., Han C.H., et al. Association between sarcopenia and metabolic syndrome in chronic obstructive pulmonary disease: The Korea National Health and Nutrition Examination Survey (KNHANES) from 2008 to 2011. COPD 2015, 12:82-89.
26. Costa T.M., Costa F.M., Moreira C.A., et al. Sarcopenia in COPD: Relationship with COPD severity and prognosis. J Bras Pneumol 2015, 41:415-421.
27. Fermoselle C., Rabinovich R., Ausin P., et al. Does oxidative stress modulate limb muscle atrophy in severe COPD patients?. Eur Respir J 2012, 40:851-862.
28. Natanek S.A., Riddoch-Contreras J., Marsh G.S., et al. Yin Yang 1 expression and localisation in quadriceps muscle in COPD. Arch Bronconeumol 2011, 47:296-302.
29. Remels A.H., Gosker H.R., Langen R.C., Schols A.M. The mechanisms of cachexia underlying muscle dysfunction in COPD. J Appl Physiol (1985) 2013, 114:1253-1262.
30. Langen R.C., Gosker H.R., Remels A.H., Schols A.M. Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary disease. Int J Biochem Cell Biol 2013, 45:2245-2256.
31. Van Helvoort H.A., Heijdra Y.F., Thijs H.M., et al. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc 2006, 38:1543-1552.
32. Li H., Malhotra S., Kumar A. Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med (Berl) 2008, 86:1113-1126.
33. Ju C.R., Chen R.C. Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease. Respir Med 2012, 106:102-108.
34. van Helvoort H.A., Heijdra Y.F., de Boer R.C., et al. Six-minute walking-induced systemic inflammation and oxidative stress in muscle-wasted COPD patients. Chest 2007, 131:439-445.
35. Murton A.J., Greenhaff P.L. Physiological control of muscle mass in humans during resistance exercise, disuse and rehabilitation. Curr Opin Clin Nutr Metab Care 2010, 13:249-254.
36. Hughes V.A., Roubenoff R., Wood M., et al. Anthropometric assessment of 10-year changes in body composition in the elderly. Am J Clin Nutr 2004, 80:475-482.
37. Evans W.J. Skeletal muscle loss: Cachexia, sarcopenia, and inactivity. Am J Clin Nutr 2010, 91:1123S-1127S.
38. Maltais F., LeBlanc P., Whittom F., et al. Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD. Thorax 2000, 55:848-853.
39. Patel M.S., Natanek S.A., Stratakos G., et al. Vastus lateralis fiber shift is an independent predictor of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014, 190:350-352.
40. Cruz-Jentoft A.J., Baeyens J.P., Bauer J.M., et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing 2010, 39:412-423.
41. Ploquin C., Chabi B., Fouret G., et al. Lack of myostatin alters intermyofibrillar mitochondria activity, unbalances redox status, and impairs tolerance to chronic repetitive contractions in muscle. Am J Physiol Endocrinol Metab 2012, 302:E1000-E1008.
42. Hennebry A., Berry C., Siriett V., et al. Myostatin regulates fiber-type composition of skeletal muscle by regulating MEF2 and MyoD gene expression. Am J Physiol Cell Physiol 2009, 296:C525-C534.
43. Girgenrath S., Song K., Whittemore L.A. Loss of myostatin expression alters fiber-type distribution and expression of myosin heavy chain isoforms in slow- and fast-type skeletal muscle. Muscle Nerve 2005, 31:34-40.
44. Baan J.A., Kocsis T., Keller-Pinter A., et al. The compact mutation of myostatin causes a glycolytic shift in the phenotype of fast skeletal muscles. J Histochem Cytochem 2013, 61:889-900.